Mecobalamin

Identification

Name

Mecobalamin

Accession Number

DB03614

Description

Not Available

Type

Small Molecule

Groups

Approved, Investigational

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Mecobalamin (DB03614)

×

Close

Weight

Average: 1344.3823
Monoisotopic: 1343.587806391

Chemical Formula

C₆₃H₉₁CoN₁₃O₁₄P

Synonyms

• Co-methylcobalamin
• MeCbl
• Mecobalamin
• Mecobalamina
• Mecobalaminum
• Methyl vitamin B12
• Methyl(III)cobalamin
• Methylcobalamin

Pharmacology

Indication

Not Available

Associated Conditions

• Vitamin B12 Deficiency

Associated Therapies

• Dietary and Nutritional Therapies

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Not Available

Mechanism of action

Target	Actions	Organism
AMethionine synthase	cofactor	Humans

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

No interactions found.

Products

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Methylcobalamin	Injection	1 mg/1mL	Intramuscular	Perdido Key Health And Wellness Inc	2015-11-20	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
B12 1000mcg (methylcobalamin)	Tablet		Oral	Natural Factors Nutritional Products Ltd.	2004-01-20	2009-09-28

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
B-Combo	Mecobalamin (1 mg/1mL) + Dexpanthenol (1 mg/1mL) + Nicotinamide (1 mg/1mL) + Pyridoxine (1 mg/1mL) + Riboflavin (1 mg/1mL) + Thiamine chloride (1 mg/1mL)	Injection	Intramuscular	Perdido Key Health And Wellness Inc	2015-11-23	Not applicable
Co-Balamin	Mecobalamin (5 mg/1mg) + Folic acid (0.8 mg/1mg) + Resveratrol (400 mg/1mg) + Ubiquinol (200 mg/1mg)	Capsule	Oral	Home Aide Diagnostics, Inc.	2015-08-01	Not applicable
Co-Veratrol	Mecobalamin (5 mg/1mg) + Folic acid (0.8 mg/1mg) + Resveratrol (400 mg/1mg) + Ubiquinol (200 mg/1mg)	Capsule	Oral	Home Aide Diagnostics, Inc.	2015-08-01	2018-10-05
Dyzbac	Mecobalamin (1 mg/1) + Ascorbic acid (150 mg/1) + Cholecalciferol (0.0125 mg/1) + Leucovorin (1 mg/1) + Lipoic acid (125 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Resveratrol (50 mg/1) + Ubidecarenone (50 mg/1)	Tablet	Oral	Basiem	2015-10-28	2015-11-01
Dyzbac	Mecobalamin (1 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (500 [iU]/1) + Leucovorin (1 mg/1) + Lipoic acid (150 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Resveratrol (50 mg/1) + Ubidecarenone (25 mg/1)	Tablet	Oral	Basiem	2015-11-05	2016-01-01
EnLyte Extra-LN	Mecobalamin (25 ug/1) + Cobamamide (25 ug/1) + Dihydrofolic Acid (1 mg/1) + Gastric intrinsic factor (25 mg/1)	Capsule	Oral	Jaymac Pharmacueticals LLC	2019-12-16	Not applicable
Folinex	Mecobalamin (1 mg/1) + Ascorbic acid (355 mg/1) + Folic acid (1 mg/1) + Vitamin K7 (100 ug/1)	Capsule	Oral	Vivera Pharmaceuticals, Inc.	2020-02-07	Not applicable
healthy mamaBE WELL ROUNDED BE WELL ROUNDED	Mecobalamin (8 ug/1) + Ascorbic acid (120 mg/1) + Beta carotene (4000 [iU]/1) + Biotin (30 ug/1) + Calcium carbonate (200 mg/1) + Cholecalciferol (400 [iU]/1) + Copper (2 mg/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Ferrous bisglycinate (28 mg/1) + Folic acid (800 ug/1) + Magnesium oxide (30 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (2.6 mg/1) + Riboflavin (1.7 mg/1) + Thiamine chloride (1.8 mg/1) + Zinc oxide (25 mg/1)	Tablet, film coated	Oral	MATERNAL SCIENCE, LLC	2013-07-09	Not applicable
L-Methyl MC NAC	Mecobalamin (2 mg/1) + Acetylcysteine (600 mg/1) + Levomefolate calcium (6 mg/1)	Tablet, coated	Oral	Virtus Pharmaceuticals	2014-04-09	2015-02-15
L-Methyl-B6-B12	Mecobalamin (2 mg/1) + Levomefolate calcium (3 mg/1) + Pyridoxal phosphate (35 mg/1)	Tablet	Oral	Seton Pharmaceuticals	2010-08-12	2012-06-30

Categories

ATC Codes

B03BA05 — Mecobalamin

• B03BA — Vitamin B12 (cyanocobalamin and analogues)
• B03B — VITAMIN B12 AND FOLIC ACID
• B03 — ANTIANEMIC PREPARATIONS
• B — BLOOD AND BLOOD FORMING ORGANS

Drug Categories

• Antianemic Preparations
• Blood and Blood Forming Organs
• Corrinoids
• Heterocyclic Compounds, Fused-Ring
• Vitamin B Complex
• VITAMIN B12 AND FOLIC ACID
• Vitamins

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as cobalamin derivatives. These are organic compounds containing a corrin ring, a cobalt atom, an a nucleotide moiety. Cobalamin Derivatives are actually derived from vitamin B12.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Tetrapyrroles and derivatives

Sub Class

Corrinoids

Direct Parent

Cobalamin derivatives

Alternative Parents

Metallotetrapyrroles / Pentose phosphates / Monosaccharide phosphates / Benzimidazoles / Benzenoids / Fatty amides / N-substituted imidazoles / Organic phosphoric acids and derivatives / Tetrahydrofurans / Pyrrolines / Pyrrolidines / Heteroaromatic compounds / Secondary carboxylic acid amides / Secondary alcohols / Lactams / Primary carboxylic acid amides / Oxacyclic compounds / Metalloheterocyclic compounds / Azacyclic compounds / Propargyl-type 1,3-dipolar organic compounds / Organic transition metal salts / Organic oxides / Primary alcohols / Carbonyl compounds / Hydrocarbon derivatives / Transition metal alkyls / Organotransition metal compounds / Organonitrogen compounds / Organopnictogen compounds

show 19 more

Substituents

Alcohol / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzimidazole / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Cobalamin / Fatty acyl / Fatty amide / Heteroaromatic compound / Hydrocarbon derivative / Imidazole / Lactam / Metalloheterocycle / Metallotetrapyrrole skeleton / Monosaccharide / Monosaccharide phosphate / N-substituted imidazole / Organic 1,3-dipolar compound / Organic metal salt / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic salt / Organic transition metal moeity / Organic transition metal salt / Organometallic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Pentose phosphate / Primary alcohol / Primary carboxylic acid amide / Propargyl-type 1,3-dipolar organic compound / Pyrrolidine / Pyrroline / Secondary alcohol / Secondary carboxylic acid amide / Tetrahydrofuran / Transition metal alkyl

show 35 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

cobalamins (CHEBI:28115)

Chemical Identifiers

UNII

BR1SN1JS2W

CAS number

13422-55-4

InChI Key

JEWJRMKHSMTXPP-WZHZPDAFSA-L

InChI

InChI=1S/C62H90N13O14P.CH3.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);1H3;/q;;+2/p-2/t31-,34-,35-,36-,37+,41-,52-,53-,56-,57+,59-,60+,61+,62+;;/m1../s1

IUPAC Name

(10S,12R,13S,17R,23R,24R,25R,30S,35S,36S,40S,41S,42R,46R)-30,35,40-tris(2-carbamoylethyl)-24,36,41-tris(carbamoylmethyl)-46-hydroxy-12-(hydroxymethyl)-1,5,6,17,23,28,31,31,36,38,41,42-dodecamethyl-15,20-dioxo-11,14,16-trioxa-2lambda5,9,19,26,43lambda5,44lambda5,45lambda5-heptaaza-15lambda5-phospha-1-cobaltadodecacyclo[27.14.1.1^{1,34}.1^{2,9}.1^{10,13}.0^{1,26}.0^{3,8}.0^{23,27}.0^{25,42}.0^{32,44}.0^{39,43}.0^{37,45}]heptatetraconta-2(47),3,5,7,27,29(44),32,34(45),37,39(43)-decaene-2,43,44,45-tetrakis(ylium)-1,1,1-triuid-15-olate

SMILES

C1(CC[[email protected]@]2([[email protected]@H](CC(N)=O)[[email protected]@]3([[email protected]@]4([N+]5=C([[email protected]]([[email protected]@]4(CC(N)=O)C)CCC(N)=O)C(C)=C4[N+]6=C(C=C7[N+]8=C([[email protected]](C7(C)C)CCC(N)=O)C(C)=C2N3[Co-3]568([N+]2=CN([[email protected]]3O[[email protected]@H]([[email protected]@H](OP(O[[email protected]@H](CN1)C)([O-])=O)[[email protected]]3O)CO)C1=CC(C)=C(C=C21)C)C)[[email protected]]([[email protected]@]4(CC(N)=O)C)CCC(N)=O)C)[H])C)=O

References

General References

Not Available

External Links

Human Metabolome Database

HMDB0002274

KEGG Drug

D03246

KEGG Compound

C06453

PubChem Compound

71306319

PubChem Substance

46506610

ChemSpider

28534328

RxNav

29421

ChEBI

28115

ChEMBL

CHEMBL2448537

PDBe Ligand

COB

Wikipedia

Methylcobalamin

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	Vincristine Induced Peripheral Neuropathy (VIPN)	1
4	Completed	Treatment	Dementia With Vitamin B12 Deficiency	1
4	Completed	Treatment	Peripheral neuropathy	1
3	Unknown Status	Treatment	Amyotrophic Lateral Sclerosis (ALS)	1
2	Completed	Treatment	Vitamin B12 Deficiency	1
2	Recruiting	Treatment	Diabetic Neuropathies	1
2, 3	Completed	Prevention	Acute Lymphoblastic Leukaemias (ALL) / Vincristine Induced Neurotoxicity	1
2, 3	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS)	2
2, 3	Completed	Treatment	Autistic Disorder	2
2, 3	Completed	Treatment	Pulmonary Function / Type 2 Diabetes Mellitus	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Bar, chewable	Oral
Tablet	Oral
Tablet, film coated	Oral	150 mg
Tablet, film coated	Oral	300 mg
Tablet, film coated	Oral	75 mg
Injection
Tablet, film coated	Oral
Tablet	Oral
Tablet, coated	Oral
Injection	Intramuscular
Capsule
Capsule	Oral
Tablet, sugar coated	Oral
Tablet
Injection	Intramuscular	1 mg/1mL
Powder	Not applicable	1 g/1g
Capsule	Oral
Capsule, liquid filled	Oral
Kit	Oral
Tablet, chewable	Oral
Capsule, gelatin coated	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
logP	-14	ChemAxon
pKa (Strongest Acidic)	1.82	ChemAxon
pKa (Strongest Basic)	-0.44	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	13	ChemAxon
Hydrogen Donor Count	9	ChemAxon
Polar Surface Area	417 Å2	ChemAxon
Rotatable Bond Count	16	ChemAxon
Refractivity	342.79 m3·mol-1	ChemAxon
Polarizability	135.93 Å3	ChemAxon
Number of Rings	12	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	-	0.6014
Blood Brain Barrier	-	0.8526
Caco-2 permeable	-	0.6453
P-glycoprotein substrate	Substrate	0.8965
P-glycoprotein inhibitor I	Inhibitor	0.5153
P-glycoprotein inhibitor II	Inhibitor	0.6647
Renal organic cation transporter	Non-inhibitor	0.8463
CYP450 2C9 substrate	Non-substrate	0.8011
CYP450 2D6 substrate	Non-substrate	0.8117
CYP450 3A4 substrate	Substrate	0.7142
CYP450 1A2 substrate	Non-inhibitor	0.8313
CYP450 2C9 inhibitor	Non-inhibitor	0.8338
CYP450 2D6 inhibitor	Non-inhibitor	0.8608
CYP450 2C19 inhibitor	Non-inhibitor	0.7142
CYP450 3A4 inhibitor	Inhibitor	0.6587
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8552
Ames test	Non AMES toxic	0.5744
Carcinogenicity	Non-carcinogens	0.815
Biodegradation	Not ready biodegradable	0.9827
Rat acute toxicity	2.6923 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8771
hERG inhibition (predictor II)	Non-inhibitor	0.5706

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 10:52